T2DM Therapy Development Service

T2DM Therapy Development Service

T2DM, which accounts for 90% of all diabetes, is a heterogeneous and progressive disease with a variety of causative and potentiating factors. The hyperglycemia of T2DM is often inadequately controlled, hence the need for a wider selection of glucose-lowering treatments. Ace Metabolism can provide researchers engaged in drugs development and gene therapy of T2DM with more efficient function analysis and overall therapy services.

Oral Hypoglycemic Therapy of T2DM

The glucose-lowing agents offered as alternatives to insulin injection include insulin analogs, sodium/glucose cotransporter-2 (SGLT-2) inhibitors and dipeptidyl peptidase IV (DPP-IV) inhibitors. By increasing β-cell insulin secretion, delaying gastric emptying, and reducing glucagon secretion, glucagon-like peptide-1 (GLP-1) analogues successfully target and suppress post-prandial hyperglycinemia in T2DM. Metformin reduces hepatic glucose output, enhances peripheral tissue sensitivity, and stimulates GLP-1 secretion which is the first-line therapy of choice for patients with T2DM.

By modifying the peptide chain to change the biological and physicochemical characteristics of insulin, insulin analogs that are more suitable for human needs than traditional human insulin have been developed and can be used directly before meals, also known as mealtime insulin or fast-acting insulin.

Gene Therapy of T2DM

The development of T2DM is a multifactorial and polygenic process, and its pathogenesis is complex. Most genes related to T2DM are related to β-cells function related. For example, FGF21 is a secreted secretion that can regulate glucose and lipid metabolism. Its biological activity mainly involves lowering blood glucose and improving blood lipid. GLP-1 acts on islet β-cells in the pancreas, promoting insulin secretion and at the same time promoting the proliferation and differentiation of islet β-cells.

Insulin Resistance and Pancreatic beta-cell DysfunctionInsulin Resistance and Pancreatic β-cell Dysfunction (Bailey, C. J.; et al. Br Med Bull. 2018.)

Antibody Therapy of T2DM

Insulin acts by binding to the insulin receptor (INSR) on the cell surface, a process that activates cell signaling. Antibodies can activate the INSR.

In humans, autoantibodies to the INSR typically bind at the insulin binding site. In most cases, these antibodies block insulin binding, causing severe insulin resistance and T2DM. The allosteric antibodies, antibodies that do not bind at the ligand binding site of receptors, can activate cell signaling.

Our Services

Therapy research provides more options for diabetes treatment options. With the goal of scientific research of diabetes, Ace Metabolism can provide a full set of therapy development services including oral antidiabetics development and gene therapy development. Our services include but not limited to the followings.

Oral Antidiabetics Development Service for T2DM

Oral Antidiabetics Development Service for T2DM

Providing our clients with oral antidiabetics (including insulin analog) development services.

Gene Therapy Development Service for T2DM

Gene Therapy Development Service for T2DM

Providing a set of services of gene therapy schemes including gene editing for gene therapy, mRNA-based gene therapy development and vectors for gene therapy.

Antibody Therapy Development Service for T2DM

Antibody Therapy Development Service for T2DM

Providing antibody therapy services including discovering targets of T2DM therapeutic, developing and evaluating antibodies and developing allosteric antibodies to receptors.

Features of Our Services

Highly CustomizableHighly Customizable

One-stop ServicesOne-stop Services

High QualitysHigh Quality

Professional TeamProfessional Team

Ace Metabolism offers cost-effect and high-quality research services related to T2DM therapy for our clients worldwide. Our assays are developed and processed with the highest standard and the results are delivered on time without compromising quality. Please feel free to contact us .

References

  1. Bastin, M. & Andreelli, F. Dual GIP-GLP1-receptor agonists in the treatment of type 2 diabetes: a short review on emerging data and therapeutic potential. Diabetes, Metabolic Syndrome and Obesity. 2019, 12, 1973–1985.
  2. Bailey, C. J. & Day, C. Treatment of type 2 diabetes: future approaches. Br Med Bull. 2018, 126(1), 123-137.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Related Services
Related Products
logo
Contact Info
Copyright © Ace Metabolism. All Rights Reserved.
Top